Carlsberg to buy Britvic for 1,315p per share Carlsberg will also buy out Marston's from brewing joint venture Danish brewer plans to create integrated beverage business in UK Shares in Carlsberg, Britvic, Marston's all rise July 8 (Reuters) - Carlsberg (CARLb.CO), opens new tab has agreed to buy British soft drinks maker Britvic (BVIC.L), opens new tab for 3.3 billion pounds ($4.23 billion), a move the Danish brewer said would forge a UK beverage "powerhouse" and that sent both companies' shares higher. Carlsberg clinched the takeover with a sweetened bid of 1,315 pence per share - comprising cash and a special dividend of 25 pence a share - after the British company rejected 1,250 pence per share last month. The acquisition will create value for shareholders, contribute to growth and forge a combined beer and soft drink company that is unique in the UK, CEO Jacob Aarup-Andersen told investors on a conference call. "With this transaction we are creating a UK powerhouse," he said. He brushed off concerns from some analysts about integration risks, saying Carlsberg has a strong track record of running beer and soft drink businesses in several markets. Soft drinks already make up 16% of Carlsberg's volumes. COST SAVINGS As drinkers in some markets ditch beer for spirits or cut back on drinking altogether, brewers have looked to broaden their portfolio into new categories like hard seltzer, canned cocktails and cider, as well as zero-alcohol brews. Britvic sells non-alcoholic drinks in Britain, Ireland, Brazil and other international markets such as France, the Middle East and Asia. Carlsberg said the deal will deliver a number of benefits, including cost and efficiency savings worth 100 million pounds ($128 million) over five years as it takes advantage of common procurement, production and distribution networks. It will also see Carlsberg take over Britvic's bottling agreement with PepsiCo (PEP.O), opens new tab. Carlsberg already bottles PepsiCo drinks in several markets and there is scope to add more geographies in future, Aarup-Andersen said. arlsberg halted share buy backs on Monday as a result of the deal. Chief financial officer Ulrica Fearn said these would resume once Carlsberg reaches its revised target for net debt of 2.5 times EBITDA, from 3.5 times currently - a goal it expects to meet in 2027. "Whilst this represents a shift in the strategy away from organic top- and bottom-line growth and consistent returns to shareholders, we view it as a relatively low risk transaction with attractive financials," Jefferies analysts said in a note. Carlsberg also said on Monday it will buy out UK pub group Marston's (MARS.L), opens new tab from a joint venture for 206 million pounds. That will give it full ownership of the newly formed Carlsberg Britvic after the deal. ($1 = 0.7805 pounds) Get the latest news and expert analysis about the state of the global economy with Reuters Econ World. Sign up here. Reporting by Stine Jacobsen, Yadarisa Shabong and Emma Rumney Editing by Sherry Jacob-Phillips, Rashmi Aich, David Goodman and David Evans

On June 27, the U.S. Space Command announced that a retired Russian satellite disintegrated in low Earth orbit on June 26, generating more than 100 pieces of debris, forcing astronauts on the International Space Station to hide for about an hour. The X-platform account of the International Space Station showed that shortly after 9 p.m. Eastern Time on June 26, NASA instructed the crew on the space station to hide in their respective spacecraft for safety because NASA learned in the morning of the 26th that a satellite disintegrated near the space station. About an hour later, the crew was allowed to leave the spacecraft and the space station resumed normal operation. There are rumors on social platforms that the satellite hit six U.S. GPS satellites after the disintegration and damaged 20 Starlink satellites developed by Space Exploration Technologies Corporation (SpaceX) led by Musk, triggering speculation that the relevant satellites were deliberately disintegrated.

China is mulling over establishing a Brain-Computer Interface (BCI) standardization technical committee under its Ministry of Industry and Information Technology (MIIT), aiming to guide enterprises to enhance industrial standards and boost domestic innovation. The proposed committee, revealed by the MIIT on Monday, will work on composing a BCI standards roadmap for the entire industry development as well as the standards for the research and development of the key technologies involved, according to the MIIT. China has taken strides in developing the BCI industry over the years, not only providing abundant policy support but also generous financial investment, Li Wenyu, secretary of the Brain-Computer Interface Industrial Alliance, told the Global Times. From last year to 2024, both the central and local governments have successively issued relevant policies to support industrial development. The MIIT in 2023 rolled out a plan selecting and promoting a group of units with strong innovation capabilities to break through landmark technological products and accelerate the application of new technologies and products. The Beijing local government also released an action plan to accelerate the industry in the capital (2024-2030) this year. In 2023, there were no fewer than 20 publicly disclosed financing events for BCI companies in China, with a total disclosed amount exceeding 150 million yuan ($20.6 million), Li said. “The strong support from the government has injected momentum into industrial innovation.” The fact that China's BCI industry started later than Western countries such as the US is a reality, leading to the gap in China regarding technological breakthroughs, industrial synergy, and talent development, according to Li. To further close gaps and solve bottlenecks in BCI industrial development, Li suggested that the industry explore various technological approaches to suit different application scenarios and encourage more medical facilities powered by BCI to initiate clinical trials by optimizing the development of BCI-related ethics. Additionally, he highlighted that standard development is one of the aspects to enhance the overall level and competitiveness of the industry chain, which could, in turn, empower domestic BCI innovation. While China's BCI technology generally lags behind leading countries like the US in terms of system integration and clinical application, this has not hindered the release of Neucyber, which stands as China's first "high-performance invasive BCI." Neucyber, an invasive implanted BCI technology, was independently developed by Chinese scientists from the Chinese Institute for Brain Research in Beijing. Li Yuan, Business Development Director of Beijing Xinzhida Neurotechnology, the company that co-developed this BCI system, told the Global Times that the breakthrough of Neucyber could not have been achieved without the efforts of the institute gathering superior resources from various teams in Beijing. A group of mature talents were gathered within the institute, from specific fields involving electrodes, chips, algorithms, software, and materials, Li Yuan said. Shrugging off the outside world's focus on China’s competition with the US in this regard, Li Yuan said her team doesn’t want to be imaginative and talk too much, but strives to produce a set of products step by step that can be useful in actual applications. In addition, Li Wenyu also attributed the emergence of Neucyber to the independent research atmosphere and the well-established talent nurturing mechanism in the Chinese Institute for Brain Research. He said that to advance China’s BCI industry, it is necessary not only to cultivate domestic talents but also to introduce foreign talents to enhance China's research and innovation capabilities. The proposed plan for establishing the BCI standardization technical committee under the MIIT will solicit public opinions until July 30, 2024.

US Secretary of State Antony Blinken declared at the Munich Security Conference: "If you're not at the table in the international system, you're going to be on the menu." The arrogant thinking of American political elites is evident: Whoever does not comply with the US will be excluded from the table of the American-led system and put on the menu. How arrogant. The US is actively pushing for "decoupling" from China and trying to persuade the entire West to "decouple" from China, using the term "de-risking." Washington hopes to ultimately contain China's development in order to maintain American hegemony. However, this time, Washington is facing a historically experienced and strategically rich Eastern civilization. Previous opponents targeted by the US have chosen to confront the US strategically. The US not only has the strongest technological and military capabilities but also controls global financial and information networks with a large number of allies. Those countries that had engaged in direct confrontations had suffered losses. Some of them had disintegrated, some had been weakened, and some had fallen into difficulties. However, what Washington sees from China is strategic composure and resilience. China is now staging an unprecedented and grand "Tai Chi." However, some Chinese people feel that this is not enough: Why can't we confront the US head-on? But I want to say that this is precisely the brilliance of China. This grand "Tai Chi" is about dismantling the pressure the US is putting on China. Europe is different from the US. A European diplomat once said in private that the topic of China has become toxic in the US, but in Europe, it is still possible to openly display friendliness toward China. There is genuine competition between the Europe and China despite Europe leans more toward the US between China and the US. Only in terms of ideology does the term "West" truly exist. In terms of fundamental economic interests, Europe has considerable independence. In terms of security, their attitude toward China also differs greatly from that of the US. In the Asia-Pacific region or China's periphery, the US wants to create an "Asian NATO." The specific situations of countries in dispute with China are very different. China has enormous influence in the region, is the largest trading partner of the vast majority of countries in the region and has friendly relations with most countries in the region. The disputes with countries are not fundamental strategic conflicts, and China has the ability to manage disputes with each specific country and push them to move toward neutrality to varying degrees without being tied to the US' policy toward China. China has a lot of trading partners and stakeholders in the US. The trade volume between China and the US, despite the decline, reached $664.4 billion in 2023, which shows China's huge presence in the US, and is the bond of the two countries in the current situation. The US is not a country where the political elites can have absolute say, and the huge interests have forced the US president and senior officials to repeatedly proclaim that they "don't want to decouple from China" and instead they want to "manage the US-China competition" and see "preventing a war with China" as clearly in everyone's best interest. China should engage in a "strategic battle" with the US at the closest possible distance. We need to maintain friendly relations with certain forces within the US, speed up the resumption of flights between the two countries, increase personnel exchanges and completely reverse the downturn of China-US contacts during the pandemic. In addition to the above dismantling, we also have the huge increment in the "Belt and Road." This initiative will increase China's power to compete with the US, greatly extending the front line that the US needs to maintain in containing China, making the US more powerless. In order to dismantle the US strategy toward China, China must become more diversified while maintaining strategic consistency. Our national diplomacy toward the US is very principled, rational and determined, which is clearly different from other countries targeted by the US. Our public diplomacy toward the US needs to be unique, with both "anti-American voices" and efforts to maintain friendly relations between the two societies and further expand economic and practical cooperation with the US. Just as eagles have their own way of flying and doves have their own formation, just as we see the US as complex, China must also be seen as complex in the eyes of the US. China is both a geopolitical concern and a profitable investment destination for them, and is one of the largest trading partners that is difficult to replace. Some American political elites proclaim China as an "enemy," but it is important to make the majority of Americans feel that China is not. No matter how intense the struggles between China and the US may be, we cannot shape the entire US toward an enemy direction. China has to make the US political elites recognize that it is futile to deal with China in the same way as it historically dealt with the Soviet Union and other major powers. Furthermore, willingly or unwillingly, coexistence and cooperation with China will be their only choice.

White House spokeswoman Karina Jean-Pierre denied a report in the U.S. media on the 8th that President Joseph Biden did not receive treatment for Parkinson's disease. Biden had the first televised debate of the 2024 presidential election with Republican opponent Donald Trump on June 27, and his poor performance on the spot triggered discussions about his physical condition. The New York Times reported that a doctor specializing in the treatment of Parkinson's disease had "visited" the White House eight times from August last year to March this year. Facing the media's questions about Biden's health, Jean-Pierre asked and answered himself at a regular White House press conference on the 8th: "Has the president received treatment for Parkinson's disease? No. Is he currently receiving treatment for Parkinson's disease? No, he is not. Is he taking medication for Parkinson's disease? No." Jean-Pierre said Biden had seen a neurologist three times, all related to his annual physical examination. She also took out the report issued by the doctor after Biden's most recent physical examination in February this year. The report said, "An extremely detailed neurological examination was once again reassuring" because no symptoms consistent with stroke, multiple sclerosis or Parkinson's disease were found. The doctor who went to the White House mentioned by the New York Times is Kevin Kanal, a neurology and movement disorder expert at the Walter Reed National Military Medical Center in Maryland and an authority on Parkinson's disease. Jean-Pierre suggested that the doctor might have come to treat military personnel on duty at the White House.